This rethinking of scientific training is particularly important as innovation in biomedical research is being avoided by pharmaceutical companies, who are becoming more averse to risk. As the editorial says "Whereas previously pharmaceutical companies took on the risk of investigating potential drugs, now it is more likely to be small biotech companies, often spin-offs from universities doing the underlying basic research, which do so." The editorial notes however that this interface can pose problems with potential conflicts of interest for scientist and universities.
The Lancet